Last reviewed · How we verify
Elocon 0.1 % Topical Cream
Mometasone furoate is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.
Mometasone furoate is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis), Atopic dermatitis, Contact dermatitis.
At a glance
| Generic name | Elocon 0.1 % Topical Cream |
|---|---|
| Also known as | Mometasone furoate 0.1% |
| Sponsor | Jacob Pontoppidan Thyssen |
| Drug class | Topical corticosteroid (Class III/IV potency) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Mometasone furoate binds to glucocorticoid receptors in skin cells, inhibiting the production of inflammatory mediators such as cytokines and prostaglandins. This reduces erythema, pruritus, and other signs of inflammation in dermatological conditions. As a potent topical steroid, it has both anti-inflammatory and immunosuppressive effects localized to the site of application.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)
- Atopic dermatitis
- Contact dermatitis
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
Key clinical trials
- Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. (PHASE3)
- Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis (NA)
- Topical Steroids & Bacterial Decolonization for Radiation Dermatitis (PHASE2)
- Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis (PHASE4)
- Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus (NA)
- Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation (PHASE3)
- A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elocon 0.1 % Topical Cream CI brief — competitive landscape report
- Elocon 0.1 % Topical Cream updates RSS · CI watch RSS
- Jacob Pontoppidan Thyssen portfolio CI